.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
McKinsey
Federal Trade Commission
Colorcon
Medtronic
Mallinckrodt
Teva
QuintilesIMS
Farmers Insurance

Generated: December 16, 2017

DrugPatentWatch Database Preview

Ani Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS, and what generic alternatives to ANI PHARMS drugs are available?

ANI PHARMS has one hundred and thirty-two approved drugs.

There is one US patent protecting ANI PHARMS drugs.

There are fourteen patent family members on ANI PHARMS drugs in eleven countries and twenty-eight supplementary protection certificates in nine countries.

Summary for Ani Pharms

International Patents:14
US Patents:1
Tradenames:73
Ingredients:67
NDAs:132
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms IncCHLORPROPAMIDEchlorpropamideTABLET;ORAL089447-001Nov 17, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms IncIBUPROFENibuprofenTABLET;ORAL072903-001Dec 19, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms IncPROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEhydrochlorothiazide; propranolol hydrochlorideTABLET;ORAL070705-001Oct 1, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani PharmsPROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDEdextromethorphan hydrobromide; promethazine hydrochlorideSYRUP;ORAL011265-002Apr 2, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Ani Pharms IncPROCAINAMIDE HYDROCHLORIDEprocainamide hydrochlorideTABLET, EXTENDED RELEASE;ORAL088959-001Dec 2, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani PharmsPROMETHAZINE HYDROCHLORIDE PLAINpromethazine hydrochlorideSYRUP;ORAL008381-004Apr 18, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Ani PharmsPHENERGAN W/ CODEINEcodeine phosphate; promethazine hydrochlorideSYRUP;ORAL008306-004Apr 2, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Ani Pharms IncTHIORIDAZINE HYDROCHLORIDEthioridazine hydrochlorideCONCENTRATE;ORAL089603-001Nov 9, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani PharmsPHENERGAN VC W/ CODEINEcodeine phosphate; phenylephrine hydrochloride; promethazine hydrochlorideSYRUP;ORAL008306-005Apr 2, 1984DISCNYesNo► Subscribe► Subscribe► Subscribe
Ani Pharms IncTHIORIDAZINE HYDROCHLORIDEthioridazine hydrochlorideTABLET;ORAL088456-001May 17, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ani Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms IncBRETHINEterbutaline sulfateTABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987► Subscribe► Subscribe
Ani Pharms IncBRETHINEterbutaline sulfateTABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms IncBRETHINEterbutaline sulfateTABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms IncBRETHINEterbutaline sulfateTABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983► Subscribe► Subscribe
Ani Pharms IncLITHOBIDlithium carbonateTABLET, EXTENDED RELEASE;ORAL018027-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-003Apr 19, 1983► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ani Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ani Pharms Drugs

Country Document Number Estimated Expiration
Spain2333306► Subscribe
European Patent Office1432411► Subscribe
Japan2005508922► Subscribe
Japan4369752► Subscribe
South Korea20040084890► Subscribe
Norway20041740► Subscribe
Germany60233668► Subscribe
MexicoPA04003234► Subscribe
World Intellectual Property Organization (WIPO)03028708► Subscribe
Austria442134► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ani Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80045Netherlands► SubscribePRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
1999Austria► SubscribePRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
C0008Belgium► SubscribePRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C0090France► SubscribePRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
2013 00059Denmark► SubscribePRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
AstraZeneca
Cerilliant
Teva
Mallinckrodt
McKesson
Daiichi Sankyo
Chubb
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot